Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achieves disease control in approximately 70%–85% of pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Onco Targets Ther
Hoofdauteurs: Spitaleri, Gianluca, Biffi, Roberto, Barberis, Massimo, Fumagalli, Caterina, Toffalorio, Francesca, Catania, Chiara, Noberasco, Cristina, Lazzari, Chiara, de Marinis, Filippo, De Pas, Tommaso
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2015
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548749/
https://ncbi.nlm.nih.gov/pubmed/26316776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S81558
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items